GSK defends Avandia against findings of CV risk by ICES group

17 December 2007

Concerns about the cardiovascular safety of glitazone drugs were raised once again with the publication of the first population-based study of these blockbuster diabetes drugs in the December 12 issue of the Journal of the American Medical Association. Canadian researchers assessed 159,026 patients on two popular medications belonging to this class and found that they significantly raised the chances of suffering a deadly heart attack.

A team from the Institute for Clinical Evaluative Sciences, in Toronto, explored three distinct outcomes using Ontario health care databases: hospital visits for congestive heart failure and heart attacks, death from any cause and exposure to specific drugs. Compared to other diabetes pills, Avandia (rosiglitazone) and its rival glitazone Actos (pioglitazone) were associated with a 60% relative increase in heart failure, 40% relative increase in heart attacks and 30% relative increase in death, according to the JAMA article.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight